Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

2.1 Venetoclax (Venclyxto, AbbVie) in combination with a hypomethylating agent is indicated for 'the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics for venetoclax.

2.3 The cost of venetoclax is £299.34 for 7×100 mg tablets (excluding VAT; BNF online accessed September 2021). The cost of azacitidine is £220 per 100‑mg vial (excluding VAT; BNF online accessed September 2021). The company has a commercial arrangement. This makes venetoclax available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.